Steven Pipe
University of Michigan
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven Pipe as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:04 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03569891 · HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCSL Behring · completed · Hemophilia B · principal investigator
- Ph2NCT03489291 · Dose Confirmation Trial of AAV5-hFIXco-PaduaCSL Behring · completed · Hemophilia B · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Training Grant in Molecular and Translational HematologyT32HL007622 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2014 to 2017 · $5,637 awarded in 2017Same name and institution; not confirmed by an ID
- Factor VIII Bioengineered for Improved Secretion EfficiencyR01HL082619 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2005 to 2008 · $329,646 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:04 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.N Engl J Med · 2022366 citationsRCR 28.6
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.Lancet Haematol · 2019332 citationsRCR 20.1
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.N Engl J Med · 2023316 citationsRCR 33.0
- 255 citationsRCR 19.5
- Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.N Engl J Med · 2023182 citationsRCR 18.0
- Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.Lancet Haematol · 2023104 citationsRCR 11.3
- 86 citationsRCR 19.9
- Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.Lancet Haematol · 202464 citationsRCR 7.8
- Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.J Thromb Haemost · 202458 citationsRCR 8.5
- 43 citationsRCR 12.0